1. Гастроэнтерология. Национальное руководство / Под ред. В. Т. Ивашкина, Т. Л. Лапиной. М.: ГЭОТАР Медиа, 2008. 1. Gastroenterology. national manual / Ed.: V.T. Ivashkin, T.L.Lapina. M.: GEOTAR Media, 2008. 2. Воробьев Г. И., Халиф И. Л. Неспецифические воспа- лительные заболевания кишечника. М.: Миклош, 2008. 2. Vorob’yev G.I., Khalif I.L. Nonspecific inflammatory bowel diseases. M.: Miklosh, 2008. 3. Marchal J., Hilsden R. Environment and epidemiology of inflammatory bowel disease. In: Inflammatory bowel disease / Eds. Satsangi J., Sutherland L. Churchill- Livingstone, 2003:17-28. 4. Farrokhyar F., Swarbick E. T., Irvine E. J. A critical review of epidemiological studies in inflammatory bowel disease. Scand J Gastroenterol 2001; 36(1):2-15. 5. OCEBM Levels of Evidence Working Group. «The Oxford 2011 Levels of Evidence». Oxford Centre for Evidence-Based Medicine. 6. Dignass A., Eliakim R., Magro F., Maaser C., Cho- wers Y., Geboes K., Mantzaris G., Reinisch W., Colombel J. F., Vermeire S., Travis S., Lindsay J. O., Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012; 6(10):965-90. 7. Travis S. P., Dinesen L. Remission in trials of ulcerative colitis: what does it mean? Pract Gastroenterol 2010; 30:17-20. 8. D’Haens G., et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132:763-86. 9. Katsanos K. H., Vermeire S., Christodoulou D. K., Riis L., Wolters F., Odes S., et al. Dysplasia and cancer in inflammatory bowel disease 10 years after diagnosis: results of a population-based European collaborative follow-up study. Digestion 2007; 75:113-21. 10. Silverberg M. S., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19(Suppl A):5-36. 11. Truelove S. C., et al. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 2:1041-8. 12. Schroeder K. W., Tremaine W. J., Ilstrup D. M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317:1625-9. 13. Чашкова Е. Ю., Владимирова А. А., Неустроев В. Г. и др. Воспалительные заболевания толстой кишки — аспекты диагностики. Бюлл Восточно-Сибирского науч- ного центра СО РАМН, 2011; 4-2:209-21. 13. Chashkova Ye.Yu., Vladimirova A.A., Neustroyev V.G., et al., Inflammatory bowel diseases - diagnostics aspects. Bull Vostochno-Sibirskogo nauchnogo tsentra SO RAMN, 2011; 4-2:209-21. 14. Григорьева Г. А., Мешалкина Н. Ю. О проблеме системных проявлений воспалительных заболеваний кишечника. Фарматека. 2011; 15:44-9. 14. Grigor’yeva G.A., Meshalkina N.Yu. Issue of inflammatory bowel diseases systemic manifestations. Farmateka. 2011; 15:44-9. 63 Клинические рекомендации 1, 2015 РЖГГК он-лайн – www.gastro-j.ru colitis. Cochrane Database Syst Rev 2010 CD004115- CD004115. 30. Marshall J. K., Irvine E. J. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta- analysis. Gut 1997; 40:775-81. 31. Lamet M. A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg twice daily in patients with active mild-to-moderate ulcerative proctitis. Dig Dis Sci 2011; 56:513-22. 32. Safdi M., De Micco M., Sninsky C., Banks P., Wruble L., Deren J., et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997; 92:1867-71. 33. Sutherland L., Macdonald J. K. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006: CD000543. 34. Regueiro M., Loftus Jr.E.V., Steinhart A. H., Cohen R. D. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis 2006; 12:979-94. 35. Ford A. C., Achkar J.-P., Khan K.J, Kane S. V., Talley N. J., Marshall J. K., et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2011; 106:601-16. 36. Kane S. V., Bjorkman D. J. The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review. Rev Gastroenterol Disord 2003; 3:210-8. 37. Kane S. V., Bjorkman D. J. The efficacy of oral 5-ASAs in the reatment of active ulcerative colitis: a systematic review. Rev Gastroenterol Disord 2003; 3:210-8. 38. Gisbert J. P., Linares P. M., McNicholl A.G., Mate J., Gomollon F. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther 2009; 30:126-37. 39. Panaccione R., Ghosh S., Middleton S., et al. Infliximab, azathioprine or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis. The UC SUCCESS trial. J Crohns Colitis 2011; 5:13. 40. Gonzalez-Huix F., Fernandez-Banares F., Esteve-Comas M., Abad-Lacruz A., Cabre E., Acero D., et al. Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis. Am J Gastroenterol 1993; 88:227-32. 41. Khan K. J., Ullman T. A., Ford A. C., Abreu M. T., Abadir A., Abadir A., et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011; 106:661-73. 42. Ohkusa T., Kato K., Terao S., Chiba T., Mabe K., Murakami K., et al. Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol 2010; 105:1820-9. 43. Järnerot G., Hertervig E., Friis-Liby I., Blomquist L., Karlen P., Granno C., et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128:1805-11. 44. Lees C. W., Heys D., Ho G. T., Noble C. L., Shand A. G., Mowat C., et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther 2007; 26:411-9. 45. Van Assche G., D’Haens G., Noman M., Vermeire S., Hiele M., Asnong K., et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003; 125:1025-31. 46. Sjoberg M., Walch A., Meshkat M., Gustavsson A., Jarnerot G., Vogelsang H., et al. Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid- refractory ulcerative colitis: a retrospective observational study. Inflamm Bowel Dis 2012; 18(2):212-8. 47. Sokol H., Seksik P., Carrat F., Nion-Larmurier I., Vienne A., Beaugerie L., et al. Usefulness of 15. Issa M., Vikayapal A., Gracham M. B., et al. Impact of Clostridium difficile in inflammatory bowel disease patients. Clin Gastroenterol Hepatol 2007; 5:345-51. 16. Rodeman J. F., Dubberke E. R., Reske K. A., et al. Incidence of Clostridium difficile in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5:339-44. 17. Issa M., Ananthakrishnan A. N., Binion D. G. Clostri- dium difficile and inflammatory bowel disease. Inflamm Bowel Dis 2008; 14:1432-42. 18. Nguyen G. C., Kaplan G. G., Harris M. L., et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008; 103:1443-50. 19. Mindenmark M., Larsson A. Rulling out IBD estimation of the possible economic effects of pre-endoscopic screening with F-calprotectin. Clin Biochem 2012; 45:552-5. 20. Costa F., Mumolo M. G., Bellini M., Romano M. R., Ceccarelli L., Arpe P., et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis 2003; 35:642-7. 21. Корнеева О. И., Ивашкин В. Т. Антибиотикоассоци- ированный колит: патоморфология, клиника, лечение. Рос журн гастроэнтерол гепатол колопроктол 2007; 17(3):65-71. 21. Korneyeva O.I., Ivashkin V.T. Antibiotic-associated colitis: pathomorphology, clinical presentation, treat- ment. Ros zhurn gastroenterol gepatol koloproktol 2007; 17(3):65-71. 22. Ивашкин В. Т., Шептулин А. А., Шифрин О. С., Галимова С. Ф., Юрманова Е. Н. Микроскопический колит: клинические формы, диагностика, лечение. Рос журн гастроэнтерол гепатол колопроктол 2006; 16(6):56-60. 22. Ivashkin V.T., Sheptulin A.A., Shifrin O.S., Galimova S.F., Yurmanova Ye.N. Microscopic colitis: clinical forms, diagnostics, treatment. Ros zhurn gastroenterol gepatol koloproktol 2006; 16(6):56-60. 23. Голованчикова В. М., Шифрин О. С., Ивашкин В. Т. Современные подходы к лечению хронических воспа- лительных заболеваний кишечника. Рос мед вести 2009; 14(3):29-37. 23. Golovanchikova V.M., Shifrin O.S., Ivashkin V.T. Modern approaches to treatment of chronic inflammatory bowel diseases. Ros med vesti 2009; 14(3):29-37. 24. Белоусова Е. А., Никитина Н. В., Цодикова О. М. Лечение язвенного колита легкого и среднетяжелого течения. Фарматека 2013; 2:42-6. 24. Belousova Ye.A., Nikitina N.V., Tsodikova O.M. Treatment of mild and moderate ulcerative colitis. Farmateka 2013; 2:42-6. 25. Халиф И. Л. Лечебная тактика при язвенном колите. Рос журн гастроэнтерол гепатол колопроктол 2006; 16(3):58-62. 25. Khalif I.L. Medical tactics at ulcerative colitis. Ros zhurn gastroenterol gepatol koloproktol 2006; 16(3):58- 62. 26. Dignass A., et al. Second EUROPEAN evidence-based Consensus on the diagnosis and management of ulcerative colitis: Current management. J Crohn’s Colitis,Reprinted from: 2012; 6(10):991-1030. 27. Халиф И. Л. Принципы лечения язвенного колита (рекомендации российской группы по изучению воспа- лительных заболеваний кишечника). Колопроктология 2006; 2:31-3. 27. Khalif I.L. Principles of treatment of ulcerative colitis (guidelines of the Russian group on inflammatory bowel diseases). Koloproctologiya 2006; 2:31-3. 28. Su C., Lewis J. D., Goldberg B., Brensinger C., Lichtenstein G. R. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology 2007; 132:516-26. 29. Marshall J. K., Thabane M., Steinhart A. H., Newman J. R., Anand A., Irvine E. J. Rectal 5-amino- salicylic acid for induction of remission in ulcerative Клинические рекомендации 64 1, 2015 РЖГГК он-лайн – www.gastro-j.ru of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006; 55:47- 53. 65. Eaden J. A., Abrams K. R., Mayberry J. F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48:526-35. 66. Jess T., Loftus Jr E. V., Velayos F. S., Harmsen W. S., Zinsmeister A. R., Smyrk T. C., et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology 2006; 130:1039-46. 67. Bergeron V., Vienne A., Sokol H., Seksik P., Nion- Larmurier I., Ruskone-Fourmestraux A., et al. Risk factors for neoplasia in inflammatory bowel disease patients with pancolitis. Am J Gastroenterol 2010;105(11):2405- 11. 68. Rutter M., Saunders B., Wilkinson K., Rumbles S., Schofield G., Kamm M., et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126:451-9. 69. Справочник по колопроктологии / Под ред. Ю. А. Шелыгина, Л. А. Благодарного. М.: Литтерра, 2012:460-522. 69. Manual on coloproctology / ed.: Yu.A. Shelygin, L.A. Blagodarny. M.: Litterra, 2012 : 460-522 70. Richards D. M., Hughes S. A., Irving M. H., Scott N. A. Patient quality of life after successful restora- tive proctocolectomy is normal. Colorectal Dis 2001; 3:223-6. 71. McLaughlin S.D., Clark S. K., Thomas-Gibson S., Tekkis P., Ciclitira P. J., Nicholls R. J. Guide to endoscopy of the ileoanal pouch following restorative proctocolectomy with ileal pouch-anal anastomosis; indications, technique, and management of common findings. Inflamm Bowel Dis 2009; 15:1256-63. 72. Berndtsson I., Oresland T. Quality of life before and after proctocolectomy and IPAA in patients with ulcerative proctocolitis — a prospective study. Colorectal Dis 2003; 5:173-9. 73. Marcello P. W., Roberts P. L., Schoetz Jr.D.J., Coller J. A., Murray J. J., Veidenheimer M. C. Long- term results of the ileoanal pouch procedure. Arch Surg 1993; 128:500-3 discussion 503-4. 74. Sagar P. M., Pemberton J. H. Ileoanal pouch function and dysfunction. Dig Dis 1997; 15:172-88. 75. Meagher A. P., Farouk R., Dozois R. R., Kelly K. A., Pemberton J. H. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg 1998; 85:800-3. 76. Setti-Carraro P., Ritchie J. K., Wilkinson K. H., et al. The first 10 years’ experience of restorative proctocolectomy for ulcerative colitis. Gut 1994; 35:1070- 5. 77. Fazio V. W., Ziv Y., Church J. M., et al. Ileal pouch- anal anastomoses complications and function in 1005 patients. Ann Surg 1995; 222:120-7. 78. Belliveau P., Trudel J., Vasilevsky C. A., et al. Ileoanal anastomosis with reservoirs: complications and long-term results. Can J Surg 1999; 42:345-52. 79. Pinto R. A., Canedo J., Murad-Regadas S., Regadas S. F., Weiss E. G., Wexner S. D. Ileal pouch- anal anastomosis in elderly patients: is there a difference in morbidity compared with younger patients? Colorectal Dis 2011; 13:177-83. 80. Church J. M. Functional outcome and quality of life in an elderly patient with an ileal pouch-anal anastomosis: a 10-year follow up. Aust N Z J Surg 2000; 70:906-7. 81. Chapman J. R., Larson D. W., Wolff B. G., Dozois E. J., Cima R. R., Pemberton J. H., et al. Ileal pouch-anal anastomosis: does age at the timeof surgery affect outcome? Arch Surg 2005; 140:534-40. 82. Delaney C. P., Dadvand B., Remzi F. H., Church J. M., Fazio V. W. Functional outcome, quality of life, and complications after ileal pouch-anal anastomosis in selected septuagenarians. Dis Colon Rectum 2002; 45:890-4. co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010; 59:1363-8. 48. Reinisch W., Sandborn W. J., Rutgeerts P., Feagan B. G., Rachmilewitz D., Hanauer S. B., et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis 2012; 18:201-11. 49. Chebli L. A., Chaves L. Dd.M., Pimentel F. F., Guerra D. M., Barros R. Md.F., Gaburri P. D., et al. Azathioprine maintains long-term steroid-free remission through 3 years in patients with steroid-dependent ulcerative colitis. Inflamm Bowel Dis 2010; 16:613-9. 50. Randall J. S.B., Warren B. F., Travis S. P., Mor- tensen N. J., George B. D. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. Br J Surg 2010; 97:404-9. 51. Lennard-Jones J.E., Ritchie J. K., Hilder W., Spicer C. C. Assessment of severity in colitis: a preli- minary study. Gut 1975; 16:579-84. 52. Travis S. P., Farrant J. M., Ricketts C., et al. Predicting outcome in severe ulcerative colitis. Gut 1996; 38:905-10. 53. Lindgren S. C., Flood L. M., Kilander A. F., Lof- berg R., Persson T. B., Sjodahl R. I. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998; 10:831-5. 54. Benazzato L., D’Inca R., Grigoletto F., Perissinotto E., Medici V., Angriman I., et al. Prognosis of severe attacks in ulcerative colitis: effect of intensive medical treatment. Dig Liver Dis 2004; 36:461-6. 55. Almer S., Bodemar G., Franzen L., Lindstrom E., Nystrom P., Strom M. Use of air enema radiography to assess depth of ulceration during acute attacks of ulcerative colitis. Lancet 1996; 347:1731-5. 56. Carbonnel F., Lavergne A., Lemann M., Bitoun A., Valleur P., Hautefeuille P., et al. Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci 1994; 39:1550-7. 57. Ferrante M., Vermeire S., Katsanos K. H. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis 2007; 13(2):123-8. 58. Gonzalez-Lama Y., Fernandez-Blanco I., Lopez-San- Roman A. Open-label infliximab therapy in ulcerative colitis: a multicenter survey of results and predictors of response. Hepatogastroenterology 2008; 55(86-87):1609-14. 59. Fasanmade A. A., Adedokun O. J., Olson A., Strauss R., Davis H. M. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther 2010; 48(5):297-308. 60. Oussalah A., Evesque L., Laharie D., Roblin X. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol 2010; 105(12):2617-25. 61. Головенко А. О., Халиф И. Л., Головенко О. В., Веселов В. В. Предикторы эффективности инфликси- маба у больных с тяжелой атакой язвенного колита. Рос журн гастроэнтерол гепатол колопроктол 2013; 23(5):65-73. 61. Golovenko A.O., Khalif I.L., Golovenko O.V., Veselov V.V. Predictors of efficacy of infliximab at patients with severe attack of ulcerative colitis. Ros zhurn gastroenterol gepatol koloproktol 2013; 23:65-73. 62. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States. Am J Respir Crit Care Med 2005; 172(9):1169-227. 63. Rahier J. F., et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009; 3(2):47-91. 64. Ardizzone S., Maconi G., Russo A., Imbesi V., Colombo E., Bianchi P. G. Randomised controlled trial 65 Клинические рекомендации 1, 2015 РЖГГК он-лайн – www.gastro-j.ru with ileal reservoir: pathological and histochemical study of mucosal biopsy specimens. J Clin Pathol 1987; 40:601- 7. 99. Setti Carraro P. G., Talbot I. C., Nicholls J. R. Patterns of distribution of endoscopic and histological changes in the ileal reservoir after restorative proctocolectomy for ulcerative colitis. A long-term follow-up study. Int J Colorectal Dis 1998; 13:103-7. 100. Ferrante M., D’Hoore A., Vermeire S., et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis 2009; 15:1062-70. 101. Lake J. P., Firoozmand E., Kang J. C., Vassiliu P., Chan L. S., Vukasin P., et al. Effect of high-dose steroids on anastomotic complications after proctocolectomy with ileal pouch-anal anastomosis. J Gastrointest Surg 2004; 8:547-51. 102. Mahadevan U., Loftus Jr.E.V., Tremaine W. J., Pemberton J. H., Harmsen W. S., Schleck C. D., et al. Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications. Inflamm Bowel Dis 2002; 8:311-6. 103. Pugliese D., Armuzzi A., Rizzo G., et al. Effect of anti-TNF-alpha treatment on short-term post-operative complications in patients with inflammatory bowel disease. Gut 2010; 59(Suppl III): A13. 104. Subramanian V., Pollok R. C., Kang J. Y., Kumar D. Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators. Br J Surg 2006; 93:793-9. 105. Yang Z., Wu Q., Wang F., Wu K., Fan D. Meta- analysis: effect of preoperative infliximab use on early postoperative complications in patients with ulcerative colitis undergoing abdominal surgery. Aliment Pharmacol Ther 2012; 36(10):922-8. 106. Dignass A., Lindsay J. O., Sturm A., Windsor A., Colombel J. F., Allez M. et al. Second European evidence- based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012. 6(10):991-1030. 107. Simchuk E. J., Thirlby R. C. Risk factors and true incidence of pouchitis in patients after ileal pouch-anal anastomoses. World J Surg 2000; 24:851-6. 108. Stahlberg D., Gullberg K., Liljeqvist L., Hellers G., Lofberg R. Pouchitis following pelvic pouch operation for ulcerative colitis. Incidence, cumulative risk, and risk factors. Dis Colon Rectum 1996; 39:1012-8. 109. Penna C., Tiret E., Kartheuser A., Hannoun L., Nordlinger B., Parc R. Function of ileal J pouch- anal anastomosis in patients with familial adenomatous polyposis. Br J Surg 1993; 80:765-7. 110. Tjandra J. J., Fazio V. W., Church J. M., Oakley J. R., Milsom J. W., Lavery I. C. Similar functional results after restorative proctocolectomy in patients with familial adenomatous polyposis and mucosal ulcerative colitis. Am J Surg 1993; 165:322-5. 111. Shen B., Achkar J. P., Lashner B. A. Irritable pouch syndrome: a new category of diagnosis for symptomatic patients with ileal pouch-anal anastomosis. Am J Gastroenterol 2002; 97 (4):972-7. 83. Olsen K. O., Joelsson M., Laurberg S., Oresland T. Fertility after ileal pouch-anal anastomosis in women with ulcerative colitis. Br J Surg 1999; 86:493-5. 84. Ording O. K., Juul S., Berndtsson I., Oresland T., Laurberg S. Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. Gastroenterology 2002; 122:15- 9. 85. Gorgun E., Remzi F. H., Goldberg J. M., Thornton J., Bast J., Hull T. L., et al. Fertility is reduced after restorative proctocolectomy with ileal pouch-anal anastomosis: a study of 300 patients. Surgery 2004; 136:795-803. 86. Johnson P., Richard C., Ravid A., Spencer L., Pinto E., Hanna M., et al. Female infertility after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum 2004; 47:1119-26. 87. Oresland T., Palmblad S., Ellstrom M., Berndtsson I., Crona N., Hulten L. Gynaecological and sexual function related to anatomical changes in the female pelvis after restorative proctocolectomy. Int J Colorectal Dis 1994; 9:77-81. 88. Alves A., Panis Y., Bouhnik Y., Maylin V., Lavergne- Slove A., Valleur P. Subtotal colectomy for severe acute colitis: a 20-year experience of a tertiary care center with an aggressive and early surgical policy. J Am Coll Surg 2003; 197:379-85. 89. Berg D. F., Bahadursingh A. M., Kaminski D. L., Longo W. E. Acute surgical emergencies in inflammatory bowel disease. Am J Surg 2002; 184:45-51. 90. Hyman N. H., Cataldo P., Osler T. Urgent subtotal colectomy for severe inflammatory bowel disease. Dis Colon Rectum 2005; 48:70-3. 91. Holubar S. D., Larson D. W., Dozois E. J., Pattana- Arun J., Pemberton J. H., Cima R. R. Minimally invasive subtotal colectomy and ileal pouch-anal anastomosis for fulminant ulcerative colitis: a reasonable approach? Dis Colon Rectum 2009; 52:187-92. 92. Marceau C., Alves A., Ouaissi M., Bouhnik Y., Valleur P., Panis Y. Laparoscopic subtotal colectomy for acute or severe colitis complicating inflammatory bowel disease: a case-matched study in 88 patients. Surgery 2007; 141:640. 93. Annibali R., Oresland T., Hulten L. Does the level of stapled ileoanal anastomosis influence physiologic and functional outcome? Dis Colon Rectum 1994; 37:321-9. 94. Burns E. M., Bottle A., Aylin P., Clark S. K., Tekkis P., Darzi A., et al. Volume analysis of outcome following restorative proctocolectomy. Br J Surg 2011; 98:408-17. 95. Tekkis P. P., Fazio V. W., Lavery I. C., Remzi F. H., Senagore A. J., Wu J. S., et al. Evaluation of the learning curve in ileal pouch-anal anastomosis surgery. Ann Surg 2005; 241:262-8. 96. Lepisto A. J.J.H. Fate of the rectum after colectomy with ileorectal anastomosis in ulcerative colitis. Scand J Surg 2005; 94:40-2. 97. Edwards C. M., George B., Warren B. F. Diversion colitis: new light through old windows. Histopathology 1999. 35(1):86-7. 98. Shepherd N. A., Jass J. R., Duval I., Moskowitz R. L., Nicholls R. J., Morson B. C. Restorative proctocolectomy
.jpg)
.png)
Комментарии